Triple

T184505
Position Surface form Disambiguated ID Type / Status
Subject European Medicines Agency E3950 entity
Predicate hasCommittee P1396 FINISHED
Object Committee for Advanced Therapies
The Committee for Advanced Therapies is a scientific body within the European Medicines Agency responsible for evaluating and providing expert opinions on advanced therapy medicinal products such as gene, cell, and tissue-engineered therapies.
E23508 NE FINISHED

How this triple was built (4 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Committee for Advanced Therapies | Statement: [European Medicines Agency, hasCommittee, Committee for Advanced Therapies]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07
Target entity: Committee for Advanced Therapies
Context triple: [European Medicines Agency, hasCommittee, Committee for Advanced Therapies]
  • A. Banting Research Foundation
    The Banting Research Foundation is a Canadian organization that funds early-career health and biomedical researchers, established to honor and continue the scientific legacy of insulin co-discoverer Sir Frederick Banting.
  • B. National Center for Advancing Translational Sciences
    The National Center for Advancing Translational Sciences is a U.S. biomedical research center focused on accelerating the development and delivery of new diagnostics, treatments, and cures by improving the translational science process.
  • C. Center for Scientific Review
    The Center for Scientific Review is the National Institutes of Health component responsible for overseeing the peer review of most grant applications to ensure scientific merit and integrity in funding decisions.
  • D. National Human Genome Research Institute
    The National Human Genome Research Institute is a U.S. government biomedical research organization that leads and funds research on the structure, function, and impact of the human genome.
  • E. Wistar Institute
    The Wistar Institute is a renowned biomedical research center in Philadelphia known for its pioneering work in cancer, immunology, and vaccine development.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg Description generation gpt-5.1
Instruction
Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: Committee for Advanced Therapies
Triple: [European Medicines Agency, hasCommittee, Committee for Advanced Therapies]
Generated description
The Committee for Advanced Therapies is a scientific body within the European Medicines Agency responsible for evaluating and providing expert opinions on advanced therapy medicinal products such as gene, cell, and tissue-engineered therapies.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07
Target entity: Committee for Advanced Therapies
Target entity description: The Committee for Advanced Therapies is a scientific body within the European Medicines Agency responsible for evaluating and providing expert opinions on advanced therapy medicinal products such as gene, cell, and tissue-engineered therapies.
  • A. Banting Research Foundation
    The Banting Research Foundation is a Canadian organization that funds early-career health and biomedical researchers, established to honor and continue the scientific legacy of insulin co-discoverer Sir Frederick Banting.
  • B. National Center for Advancing Translational Sciences
    The National Center for Advancing Translational Sciences is a U.S. biomedical research center focused on accelerating the development and delivery of new diagnostics, treatments, and cures by improving the translational science process.
  • C. Center for Scientific Review
    The Center for Scientific Review is the National Institutes of Health component responsible for overseeing the peer review of most grant applications to ensure scientific merit and integrity in funding decisions.
  • D. National Human Genome Research Institute
    The National Human Genome Research Institute is a U.S. government biomedical research organization that leads and funds research on the structure, function, and impact of the human genome.
  • E. Wistar Institute
    The Wistar Institute is a renowned biomedical research center in Philadelphia known for its pioneering work in cancer, immunology, and vaccine development.
  • F. None of above. chosen

Provenance (5 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69a25497e2f08190a040f8c6e1842643 completed Feb. 28, 2026, 2:36 a.m.
NER Named-entity recognition batch_69a25926be9c8190a4cfce66f57589d1 completed Feb. 28, 2026, 2:55 a.m.
NED1 Entity disambiguation (via context triple) batch_69a2fd0577588190a91be504e3c9f0ab completed Feb. 28, 2026, 2:34 p.m.
NEDg Description generation batch_69a2fe0b1c148190854569c3f6e03a91 completed Feb. 28, 2026, 2:39 p.m.
NED2 Entity disambiguation (via description) batch_69a2fe7676488190b0d126a7d3d75b5f completed Feb. 28, 2026, 2:40 p.m.
Created at: Feb. 28, 2026, 2:40 a.m.